个性化胰岛素计算器可安全有效纠正FDG PET/CT前高血糖
该回顾性审计在Peter MacCallum癌症中心开展,比较了经验性胰岛素方案(第1队列,115例)与个性化胰岛素计算器方案(第2队列,136例)在FDG PET/CT前纠正高血糖(血糖>10 mmol/L)的效果。结果显示,个性化方案显著减少低血糖事件(0.7% vs 5.2%;P < 0.03),缩短胰岛素至FDG注射的中位时间(108 min vs 136 min;P < 0.001),且88.3%的患者达到血糖<10.0 mmol/L,所有扫描均具诊断质量。
要点
- 个性化胰岛素计算器方案较经验性方案显著降低低血糖事件发生率(0.7% vs 5.2%;P < 0.03)。
- 该方案缩短了胰岛素至FDG注射的中位时间(108 min vs 136 min;P < 0.001)。
- 88.3%接受个性化计算器处方剂量的患者血糖降至<10.0 mmol/L,所有扫描诊断质量合格。
核心结论
- 个性化胰岛素计算器方案能有效将血糖降至目标范围,显著减少低血糖事件并缩短胰岛素至FDG注射的中位时间,同时获得诊断质量的扫描。
研究设计与样本
- 回顾性审计,纳入Peter MacCallum癌症中心2年内因高血糖(血糖>10 mmol/L)在FDG PET/CT前接受胰岛素治疗的患者。
- 第1队列为2014年4月1日至2015年3月31日使用科室既定经验性剂量胰岛素方案的患者,共115例。
- 第2队列为2015年4月1日至2016年3月31日引入个性化胰岛素计算器方案后的患者,共136例。
- 分析变量包括体重指数、计算和/或给予的胰岛素剂量、基线和最低血糖、以及至FDG注射时间。
主要发现
- 两队列基线变量相似,包括平均血糖(14.5 vs 14.4 mmol/L)和范围(10.5-22.7 vs 10.4-24.3 mmol/L)。
- 个性化胰岛素计算器方案组低血糖事件显著更少(0.7% vs 5.2%;P < 0.03)。
- 个性化方案组胰岛素至FDG注射的中位时间更短(108 min vs 136 min;P < 0.001)。
- 个性化方案组胰岛素处方范围更个体化(3-32 IU vs 4-20 IU)。
- 接受个性化计算器处方剂量的患者中88.3%达到血糖<10.0 mmol/L,所有扫描均具诊断质量。
关键数值与推荐
- 国际核医学主要学会推荐FDG PET/CT前血糖水平< 11.1 mmol/L(200 mg/dL)。
- 本研究对血糖> 10 mmol/L的患者使用胰岛素纠正高血糖。
- 个性化胰岛素计算器方案组低血糖事件发生率0.7%,经验性方案组5.2%(P < 0.03)。
- 个性化方案组从胰岛素到FDG注射的中位时间为108 min,经验性方案组为136 min(P < 0.001)。
- 接受个性化计算器处方剂量的患者中88.3%达到血糖< 10.0 mmol/L。
临床怎么用
- 对于FDG PET/CT前高血糖(血糖>10 mmol/L)患者,可采用个性化胰岛素计算器估算静脉胰岛素剂量以安全有效地降低血糖。
- 该方案有助于减少低血糖事件、缩短等待时间,并保证扫描诊断质量。
局限性
- 本研究为单中心回顾性审计,结果可能受机构实践和患者群体特征影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hyperglycaemia can influence 18F-fluorodeoxyglucose (FDG) uptake due to competition for glucose transport and phosphorylation by hexokinase. Major international nuclear medicine societies recommend blood glucose level (BGL) < 11.1 mmol/L (200 mg/dL) prior to performing FDG positron emission tomography/computed tomography (PET/CT). However, there is no consensus approach and complications of previously proposed insulin guidelines included significant hypoglycaemia, inconvenience and skeletal muscle uptake. This study aims to establish the safety and efficacy of a personalised insulin calculator protocol to estimate the dose of intravenous insulin injection for correction of hyperglycaemia prior to FDG PET/CT. RESULTS: This is a retrospective audit of all patients treated with insulin for hyperglycaemia (BGL > 10 mmol/L) prior to FDG PET/CT at the Peter MacCallum Cancer Centre over a 2-year period. Cohort 1 comprised a 12-month period (April 1, 2014-March 31, 2015) using the department's established empiric-dose insulin protocol, and Cohort 2 the 12 months (April 1, 2015-March 31, 2016) following introduction of a personalised insulin calculator protocol. Variables including body mass index, insulin-dose calculated and/or administered, BGL at baseline and nadir, and time to FDG injection were analysed. There were 115 and 136 patients treated with insulin in Cohorts 1 and 2 respectively, with similar baseline variables including mean BGL (14.5 vs 14.4 mmol/L) and range (10.5-22.7 vs 10.4-24.3 mmol/L). Use of the new personalised insulin calculator resulted in significantly fewer hypoglycaemic events (0.7% vs 5.2%; P < 0.03), shorter median time from insulin to FDG injections (108 min vs 136 min; P < 0.001) and greater individualised range in insulin prescription (3-32 IU vs 4-20 IU). The majority of patients (88.3%) receiving the personalised insulin calculator prescribed dose achieved BGL < 10.0 mmol/L. All scans obtained were of diagnostic quality. CONCLUSIONS: The use of our personalised insulin calculator protocol effectively lowered BGL to the target range, resulted in significantly fewer hypoglycaemic events and reduced median time between insulin and FDG injection compared to a pre-existing empiric protocol whilst achieving diagnostic scans.
引用
- Pattison DA, MacFarlane LL, Callahan J, et al. Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT. EJNMMI Res. 2019. PMID: 30737563. doi:10.1186/s13550-019-0480-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。